Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech / Market map

Market mapREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Healthtech & medtech market map

The healthtech and medtech industry supplies medical devices, diagnostics, digital health, health IT, and life-science tools and services to business buyers. Buyers include hospitals and health systems, physician practices, ambulatory and alternative-care sites, pharmaceutical and biotech companies, life-science laboratories, contract research and manufacturing organisations, and public or private payers; the buying decision typically involves clinical, procurement, IT, finance, and regulatory stakeholders.

Industry size
$1.1T
2025 · Low confidence
Growth
—
CAGR
Segments
7 · 29 · 124
sectors · submarkets · niches
Companies mapped
46
leaders and specialists by submarket

The map

Sectors sized by their share of the market; tiles are submarkets, coloured by attractiveness for B2B sellers. Click any block.

Where to play

Every submarket by size and attractiveness (pain × purchasing power × reachability × growth).

8842 LARGE · ATTRACTIVE SMALL · LESS ATTRACTIVE Market size (log scale) → Attractiveness for B2B sellers → Authorised distributors and value-added resellers: $23.3B, attractiveness 75, CAGR +12.6%Contract research, testing and laboratory outsourcing: $20.3B, attractiveness 75, CAGR +10.2%Molecular and specialised diagnostics: $14.8B, attractiveness 75, CAGR +6.6%Telehealth and virtual-care software: $18.0B, attractiveness 75, CAGR —Supply-chain, logistics and commercial support: $16.5B, attractiveness 75, CAGR +12.6%Clinical laboratories: $54.6B, attractiveness 75, CAGR +6.2%Specialty sales and clinical support organisations: $25.9B, attractiveness 75, CAGR +12.6%Healthcare analytics, data infrastructure and interoperability: $22.5B, attractiveness 80, CAGR —Clinical evidence and trial services: $3.2B, attractiveness 75, CAGR +7.0%Installation, commissioning and integration: $2.5B, attractiveness 75, CAGR +12.4%Maintenance, repair and compliance services: $1.7B, attractiveness 70, CAGR +12.4%Quality, compliance and lifecycle regulatory services: $1.2B, attractiveness 70, CAGR +8.0%Remote monitoring, digital therapeutics and connected-care technology: $25.0B, attractiveness 80, CAGR —Life-science informatics and laboratory software: $20.3B, attractiveness 80, CAGR +10.2%Managed operation and optimisation services: $920M, attractiveness 70, CAGR +12.4%Analytical and characterisation instruments: $65.9B, attractiveness 80, CAGR +6.0%Training and adoption services: $576M, attractiveness 60, CAGR +12.4%Point-of-care and ambulatory testing: $18.5B, attractiveness 60, CAGR +6.6%Regulatory affairs and submissions services: $3.2B, attractiveness 75, CAGR +6.5%Clinical consumables and general diagnostics: $4.5B, attractiveness 50, CAGR +5.0%Health IT and clinical workflow software: $33.0B, attractiveness 75, CAGR —Group purchasing, tendering and contract-management services: $6.2B, attractiveness 75, CAGR +12.6%Laboratory consumables and reagents: $104B, attractiveness 70, CAGR +6.0%Market access, reimbursement and health-economic services: $900M, attractiveness 60, CAGR +9.0% Laboratory consumables an…Analytical and characteri…Clinical laboratoriesPoint-of-care and ambulat…Clinical consumables and …Clinical evidence and tri…Maintenance, repair and c…Market access, reimbursem…

Distribution, channel and commercial infrastructureLife-science tools, instruments and laboratory servicesDiagnostics and laboratory productsDigital health software and connected health technologyClinical and regulatory support servicesDeployment, integration and lifecycle services · Bubble size = growth (CAGR)

Analyst's view

For B2B sellers this is a large, device-weighted market: roughly 57% of the pool sits in medical devices, with surgical/interventional, therapeutic and monitoring use cases carrying the money, and a further 18% in life-science tools, instruments and reagents where recurring consumables revenue is the most defensible annuity. The pain and the budget sit with hospital and lab procurement — capital equipment cycles, tendering, and the consumables and service tail that follows installation — which is why channel, deployment and lifecycle nodes matter even though they are currently sized as rounding errors. The map's weakest areas are the digital-health and diagnostics subtrees, which are understated and overlap with device nodes, and the absence of any buyer-side cut (IDNs, ambulatory groups, pharma and medtech sponsors) that would let a seller target a specific budget owner.

Growth drivers
  • Rising adoption of AI-enabled diagnostics, robotics, and other differentiated technologies is increasing innovation and investment across MedTech [1][2]
  • Expansion of MedTech into alternative care settings creates new procurement demand outside traditional hospital channels [2]
  • Continued outsourcing and investment in clinical development, laboratory workflows, and life-science tools support demand for research products and services [2]
  • Digital transformation, interoperability, remote monitoring, and care-delivery efficiency requirements drive health IT and digital-health procurement [2]
  • European medtech employment above 950,000 and record patent filings indicate continued product development and innovation capacity [3][5]
  • Growth in diabetes care, minimally invasive therapies, structural heart, and other chronic-disease management areas expands device and diagnostic demand [2]
Headwinds
  • Europe's medtech market grew only 1.8% in 2025, well below its roughly 6% decade average, indicating slow underlying demand growth [3][5][6]
  • Europe's share of the global medtech market fell to 25.6% from 26.4%, suggesting relative share loss to faster-growing markets [3][5][6]
  • The number of public MedTech companies in the US and Europe fell another 17% in 2025, reflecting consolidation and pressure on non-leading companies [1]
  • Tariff uncertainty, trade headwinds, and macroeconomic uncertainty constrain capital budgets and slow purchasing decisions [9]
  • A two-tier industry structure concentrates growth and value in high-performing, high-differentiation innovators, making it harder for undifferentiated suppliers to win [1]
  • Regulatory approval, clinical validation, reimbursement, and evidence requirements lengthen sales cycles and raise selling costs

All segments 160

Sizes in USD, latest available year. Confidence reflects the sources behind each figure.

SegmentSizeGrowthScoreMaturityConfidence
Medical devices$623B+6.3%—MatureMediumSurgical and interventional devices$193B+6.3%—GrowthMediumAmbulatory surgery centre and outpatient procedure-device buyers——70——Consumables and single-use procedure-attached revenue (hospital and ASC)——85——Hospital operating-room surgical and interventional device suites——80——Interventional cardiology, structural heart and electrophysiology device franchises——90——Physician practice and office-based procedure buyers——60——Therapeutic and rehabilitation devices$150B+6.3%—GrowthLowDialysis machines, consumables and home dialysis systems——85——Hospital infusion and drug-delivery pump programmes——80——Mobility aids and patient-support equipment for home and community care——65——Rehabilitation equipment and therapy-device programmes——65——Ventilators and respiratory support devices for acute and alternate care——80——Imaging and radiotherapy equipment$131B+6.3%—MatureLowBreast screening and women's imaging — mammography systems and biopsy/associated detectors——60——Hospital radiology departments — diagnostic imaging systems (CT, MRI, X-ray, ultrasound)——75——Imaging OEM service, detector and table component supply (B2B supplier tier)——55——Outpatient and ambulatory imaging centres — owned and operated diagnostic imaging——70——Radiation oncology and radiotherapy systems — linear accelerators and treatment planning——75——Patient monitoring and vital-sign devices$87.3B+6.3%—GrowthLowAcute-care inpatient monitoring——75——Ambulatory and alternative-care monitoring——70——Connected and remote patient monitoring——75——Hospital furniture, support and infection-control equipment$62.3B+6.3%—MatureLowAcute-care beds and patient handling——75——Infection-control hardware for hygiene and isolation——75——Long-term-care and alternative-site patient-support equipment——65——Sterilisation and reprocessing systems——70——Life-science tools, instruments and laboratory services$203B+10.2%80GrowthMediumLaboratory consumables and reagents$104B+6.0%70MatureMediumContract testing and QC consumables for CROs and CDMOs$15.6B+6.0%——LowAcademic and government research consumables$13.2B+5.0%——LowDiscovery and screening assay reagents for biotech and pharma research teams$12.0B+7.0%——LowProcess-development and scale-up purification consumables (columns, resins, single-use assemblies)$10.2B+8.0%——LowClinical-development sample handling and biobanking consumables$9.0B+6.0%——LowAnalytical and characterisation instruments$65.9B+6.0%80GrowthMediumDiscovery-stage molecular and proteomics characterisation platforms——70——Preclinical development and translational research characterisation platforms——70——Regulated manufacturing and quality-control characterisation systems——75——Sequencing and single-cell spatial characterisation platforms——80——Contract research, testing and laboratory outsourcing$20.3B+10.2%75GrowthLowAcademic and government-funded research outsourcing——55——Clinical-stage bioanalytical and clinical trial support laboratory services——85——Discovery-stage assay and mechanism-of-action outsourcing for pharma and biotech——80——Preclinical safety, bioanalytical and validation outsourcing for pharma and biotech——80——Stability, specification and quality-control laboratory outsourcing——70——Life-science informatics and laboratory software$20.3B+10.2%80GrowthLowAcademic and research institution laboratory data management——55——CRO and CDMO laboratory operations and sample management——70——Pharma and biotech R&D laboratory informatics——80——Digital health software and connected health technology$98.5B+14.5%80GrowthMediumHealth IT and clinical workflow software$33.0B—75MatureLowAmbulatory and physician-practice clinical workflow and practice management——80——Care coordination and connected-care workflow platforms——80——Enterprise acute-care EHR and clinical documentation replacement——90——Interoperability, health data exchange and clinical integration middleware——85——Revenue-cycle management and patient financial operations——85——Remote monitoring, digital therapeutics and connected-care technology$25.0B—80GrowthLowAmbulatory chronic-care and digital-therapeutic management——90——Hospital and health-system remote monitoring——90——Payer-sponsored remote-care benefit and program delivery——85——Pharma and biotech connected clinical-development programs——80——Healthcare analytics, data infrastructure and interoperability$22.5B—80GrowthLowClinical analytics & AI decision support for hospitals and health systems——80——Connected-care and remote-monitoring data platforms (provider-side analytics layer)——75——Interoperability, data warehousing and master patient index (MPI) for provider networks——80——Life sciences and pharma data infrastructure, analytics and clinical decision support——75——Payer analytics, data infrastructure and interoperability——80——Telehealth and virtual-care software$18.0B—75GrowthLowAmbulatory practice virtual consultations$7.5B+14.5%80—LowHospital virtual wards and patient-facing virtual care$7.5B+14.5%90—LowClinician-to-clinician teleconsultation$3.2B+14.5%70—LowPayer-sponsored virtual care enablement$3.2B+14.5%70—LowDiagnostics and laboratory products$92.4B+4.8%75MatureMediumClinical laboratories$54.6B+6.2%75MatureMediumMulti-site hospital laboratory groups——80——Routine core-lab testing——80——Specialised and molecular assay testing——80——Point-of-care and ambulatory testing$18.5B+6.6%60GrowthLowAlternative-care sites: decentralised and employer-based testing——65——Emergency departments: time-critical point-of-care testing——80——Physician practices: acute-care rapid testing——70——Urgent-care centres: high-throughput rapid testing——80——Molecular and specialised diagnostics$14.8B+6.6%75GrowthLowHospital laboratory routine molecular infectious-disease testing$8.8B+7.0%——LowComplex genomic and specialised testing for inherited disease and oncology profiling$7.3B+10.0%——LowAssay development, biomarker validation and clinical-trial testing for biopharma$3.3B+8.0%——LowRapid and point-of-care molecular testing for acute-care decisions$2.6B+9.0%——LowClinical consumables and general diagnostics$4.5B+5.0%50MatureLowHospital core-lab specimen collection and handling consumables——75——Molecular and specialised-testing pre-analytical consumables——75——Point-of-care and ambulatory-site collection consumables——65——Reference and commercial laboratory specimen-handling consumables——70——Distribution, channel and commercial infrastructure$71.8B+12.6%75GrowthLowSpecialty sales and clinical support organisations$25.9B+12.6%75GrowthLowDiagnostic vendors — instrument placement and assay adoption——80——Healthtech software vendors — clinical-workflow implementation and adoption——80——Life-science vendors — laboratory and biopharma technical account coverage——70——Medical-device OEMs — capital-equipment and procedure-adoption coverage——90——Authorised distributors and value-added resellers$23.3B+12.6%75MatureLowDiagnostics and connected-care vendors commercialising digitally enabled products$51.7B+12.6%75—MediumCapital equipment OEMs entering fragmented European peripheral markets——65——Consumables and surgical-product manufacturers scaling recurring hospital supply——80——Life-science and clinical-supply vendors expanding into emerging Asia-Pacific markets——65——Multi-brand manufacturers consolidating channel coverage in mature Western markets——70——Supply-chain, logistics and commercial support$16.5B+12.6%75GrowthLowCapital-equipment channel entry and launch logistics for medtech OEMs entering Europe——70——Consumables and medical-supply replenishment, warehousing and inventory management—————Digital procurement, e-commerce and distributor-management infrastructure—————Emerging-market medtech distribution build-out in South-East Asia——75——Group purchasing, tendering and contract-management services$6.2B+12.6%75GrowthLowAcute-care health system enterprise procurement——90——Physician-group and ambulatory-site purchasing cooperatives——75——Provider procurement transformation and outsourced category management——80——Provider-led digital procurement and supplier-framework management——90——Clinical and regulatory support services$8.5B+8.0%75GrowthMediumClinical evidence and trial services$3.2B+7.0%75GrowthMediumPharma and biotech outsourced clinical development$63.6B———MediumMedical-device and diagnostic pre-market clinical evidence$2.1B+6.5%——LowDigital-health clinical validation and coverage evidence—————Medical-device and diagnostic post-market coverage evidence—————Regulatory affairs and submissions services$3.2B+6.5%75GrowthMediumPharma and biopharma regulatory outsourcing$8.9B+7.3%80—MediumMedtech regulatory submission and market-access support$4.6B+6.5%80—MediumDigital-health and software-as-a-medical-device regulatory support——75——Life-science tools and in-vitro diagnostic regulatory support——70——Quality, compliance and lifecycle regulatory services$1.2B+8.0%70GrowthLowPost-market surveillance, vigilance and product-safety lifecycle services$7.4B+10.0%——LowPharma & biotech GMP quality systems, inspection readiness and audit remediation$2.2B+7.6%——LowMedtech & IVD quality-system implementation and compliance audit support$735M+6.5%——LowMedtech risk-management files and product-lifecycle regulatory documentation$370M+6.5%——LowDigital health and SaMD software-quality, cybersecurity and AI/ML lifecycle compliance$260M+6.5%——LowMarket access, reimbursement and health-economic services$900M+9.0%60EmergingLowCross-buyer launch support and health-economic evidence services——80——Medtech reimbursement dossiers and HTA submissions——85——Pharma and biotech reimbursement dossiers and HTA submissions——90——Pricing analysis and market-access strategy for medtech——80——Pricing analysis and market-access strategy for pharma and biotech——85——Deployment, integration and lifecycle services$5.8B+12.4%75GrowthMediumInstallation, commissioning and integration$2.5B+12.4%75GrowthMediumHospital clinical device & platform integration (acute care and health systems)$2.3B+11.6%——MediumLife-science, pharma and research-site instrument integration and validated deployment$920M+17.4%——LowClinical and reference laboratory analyser installation, validation and LIS interfacing$780M+12.4%——LowAmbulatory and outpatient site deployment (surgical centres, imaging and clinic fit-outs)$600M+13.5%——LowMaintenance, repair and compliance services$1.7B+12.4%70MatureLowHospital clinical equipment uptime and compliance——85——Laboratory and life-science instrument reliability——75——Managed maintenance and compliance programmes——80——Managed operation and optimisation services$920M+12.4%70EmergingLowClinical software and interoperability managed services$1.6B—90—LowHospital clinical device and workflow operations$690M—90—LowLaboratory instrument and diagnostic workflow operations——70——Life-science clinical trial technology operations——75——Remote patient monitoring and virtual-care operations——90——Training and adoption services$576M+12.4%60GrowthLowHospital clinical device & diagnostic go-live training (nursing, ICU, imaging, lab bench)$780M+8.6%90—LowHealth IT application user training and onboarding curricula (EHR, clinical software, admin systems)$620M+10.3%85—LowAdministrator, revenue-cycle and IT operations training (registration, scheduling, billing, helpdesk)$300M+9.4%70—LowLaboratory and pathology analyser competency training (bench, LIS and instrument operation)$240M+9.0%70—LowLife-science and clinical-trial workforce training (GCP, regulated operations, device/drug use)$210M+11.4%75—Low

// From map to pipeline

AOS turns the most attractive niches into accounts with a reason to talk now, and prepares the outreach for your approval.

Researched by the AOS market intelligence agent from public sources; refreshed weekly. Figures are estimates with stated methods and confidence, not investment advice.